<DOC>
	<DOCNO>NCT00426764</DOCNO>
	<brief_summary>The purpose study evaluate activity romidepsin patient progressive relapsed peripheral T-cell lymphoma ( PTCL ) already treat systemic therapy .</brief_summary>
	<brief_title>A Trial Romidepsin Progressive Relapsed Peripheral T-cell Lymphoma</brief_title>
	<detailed_description>This Phase II , non-randomized , open-label , single-arm trial . This study design basis complete response [ CR CR ( u ) ] measure efficacy , base best overall response patient . The sample size 65 patient evaluable efficacy would yield low 95 % confidence limit rate CR + CR ( u ) would range 2.2 % 7.7 % , observed rate CR + CR ( u ) range 8 % 15 % . The study amend include Extension Phase , patient non-US site benefit treatment continue receive romidepsin . The Extension Study Phase active EU country currently Marketing Authorisation exist romidepsin . Patients may remain study progressive disease occur withdraw consent serious adverse event study drug administration data continue collect report patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Patients must fulfill follow criterion eligible study participation : Histologically confirm PTCL otherwise specify , angioimmunoblastic Tcell lymphoma , extranodal natural killer ( NK ) /Tcell lymphoma nasal type , enteropathy type Tcell lymphoma , subcutaneous panniculitislike Tcell lymphoma , cutaneous γδ Tcell lymphoma ( excludes mycosis fungoides Sezary syndrome ) , transform mycosis fungoides , hepatosplenic Tcell lymphoma , anaplastic large cell lymphoma ( ALCL ; anaplastic lymphoma kinase [ ALK ] 1 negative ) , patient ALK 1 express ALCL ( ALK1 positive ) relapse disease autologous stem cell transplant ( ASCT ) ; Age ≥18 year ; Written inform consent ; Progressive disease follow least one systemic therapy refractory least one prior systemic therapy ; Measurable disease accord International Workshop Response ( IWC ) criteria and/or measurable cutaneous disease ; Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; Serum potassium ≥3.8 mmol/L magnesium ≥0.85 mmol/L ( electrolyte abnormality correct supplementation meet inclusion criterion ) ; Negative urine serum pregnancy test female childbearing potential ; All woman childbearing potential must use effective barrier method contraception ( either intrauterine contraceptive device [ IUCD ] double barrier method use condom diaphragm plus spermicide ) treatment period least 1 month thereafter . Male patient use barrier method contraception treatment period least 1 month thereafter . Hormonal method contraception contraceptive pill patch ( particularly contain ethinylestradiol ) avoid due potential drug interaction . Patients ineligible entry follow criterion meet : Known central nervous system ( CNS ) lymphoma [ compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan require brain metastasis suspect clinically ] ; Chemotherapy immunotherapy within 4 week study entry ( 6 week nitrosoureas give ) ; Initiation corticosteroid study ( define 7 day prior Cycle 1 Day 1 [ C1D1 ] study drug discontinuation ) Patients treat pulse steroid discontinue steroid use 7 day prior C1D1 repeat CT scan disease assessment discontinuation corticosteroid start romidepsin ; Concomitant use anticancer therapy ; Concomitant use investigational agent ; Use investigational agent within 4 week study entry ; Any know cardiac abnormality : Congenital long QT syndrome ; QTc interval &gt; 480 millisecond ( msec ) ; A myocardial infarction within 6 month C1D1 . Patients history myocardial infraction 6 12 month prior C1D1 asymptomatic negative cardiac risk assessment ( treadmill stress test , nuclear medicine stress test , stress echocardiogram ) since event may participate ; Other significant electrocardiogram ( ECG ) abnormalities include 2nd degree atrioventricular ( AV ) block type II , 3rd degree AV block , bradycardia ( ventricular rate le 50 beats/min ) . Symptomatic coronary artery disease ( CAD ) , e.g. , angina Canadian Class IIIV . In patient doubt , patient refer cardiologist evaluation ; An ECG record screen show significant ST depression ( ST depression ≥2 mm , measure isoelectric line ST segment point 60 msec end QRS complex ) . If doubt , patient stress image study , abnormal , angiography define whether CAD present ; Congestive heart failure ( CHF ) meet New York Heart Association ( NYHA ) Class II IV definition and/or ejection fraction &lt; 40 % MUGA scan &lt; 50 % echocardiogram and/or MRI ; A known history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) ; Hypertrophic cardiomyopathy restrictive cardiomyopathy prior treatment cause ( doubt , see ejection fraction criterion ) ; Uncontrolled hypertension , i.e. , blood pressure ( BP ) ≥160/95 ; patient history hypertension control medication must stable dose ( least one month ) meet inclusion criterion ; Any cardiac arrhythmia require antiarrhythmic medication ; Serum potassium &lt; 3.8 mmol/L serum magnesium &lt; 0.85 mmol/L ( electrolyte abnormality correct supplementation meet inclusion criterion ) ; Concomitant use drug may cause significant prolongation QTc ; Concomitant use CYP3A4 significant moderate inhibitor ; Concomitant use therapeutic warfarin another anticoagulant due potential drug interaction . Use small dose anticoagulant maintain patency venous access port cannula permit ; Clinically significant active infection ; Known infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C ; Previous extensive radiotherapy involve ≥30 % bone marrow ( e.g. , whole pelvis , half spine ) , exclude patient total body irradiation part condition regimen ASCT ; Major surgery within 2 week study entry ; Previous allogeneic stem cell transplant ; Inadequate bone marrow organ function evidence : Hemoglobin &lt; 9 g/dL ( transfusion and/or erythropoietin permit ) ; Absolute neutrophil count ( ANC ) ≤1.0 × 10^9 cells/L [ patient neutropenia ( ANC 11.5 10^9 cells/L ) function disease may support granulocytecolony stimulate factor ( GCSF ) ] ; Platelet count &lt; 100 × 10^9 cells/L platelet count &lt; 75 × 10^9 cells/L bone marrow disease involvement document ; Total bilirubin &gt; 2.0 × upper limit normal ( ULN ) &gt; 3.0 × ULN presence demonstrable liver metastasis ; Aspartate transaminase/serum glutamic oxaloacetic transaminase ( AST/SGOT ) alanine transaminase/serum glutamic pyruvic transaminase ( ALT/SGPT ) &gt; 2.0 × ULN &gt; 3.0 × ULN presence demonstrable liver metastasis ; Serum creatinine &gt; 2.0 × ULN ; Patients pregnant breastfeeding ; Coexistent second malignancy history prior solid organ malignancy within previous 3 year ( exclude basal squamous cell carcinoma skin , situ carcinoma cervix ( CIN 1 ) treat curatively ) ; Any prior history hematologic malignancy ( Tcell lymphoma ) ; Any significant medical psychiatric condition might prevent patient comply study procedure ; Prior exposure romidepsin ( histone deacetylase inhibitor allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>T-cell lymphoma</keyword>
	<keyword>romidepsin</keyword>
</DOC>